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Abstract
Osteonecrosis of the jaw (ONJ) associated with the use of bisphosphonates has been rarely reported in metastatic
renal cell cancer (RCC) patients. Since the introduction of combined therapies consisting of nitrogen-containing
bisphosphonates (NBPs) and targeted agents, an increasing number of RCC patients were reported to develop
ONJ, suggesting that therapeutic angiogenesis suppression might increase the risk of ONJ in NBPs users. We per-
formed a multicenter retrospective study and reviewed literature data to assess the occurrence and to investigate the
nature of ONJ in RCC patients taking NBPs and targeted agents. Nine Italian Centers contributed to the data
collection. Patients with exposed and nonexposed ONJ were eligible for the study if they had been taking NBPs and
were receiving targeted agents at the time of ONJ diagnosis. Forty-four RCC patients were studied. Patients were
mostly male (82%), with a median age of 63 years (range, 45-85 years). Zoledronic acid (93%) and sunitinib (80%) were
the most frequently used NBP and antiangiogenic agent, respectively. Other agents included Pamidronate, ibandr-
onate, sorafenib, bevacizumab, mammalian target of rapamycin inhibitors. Forty-nine sites of ONJ were encountered,
with the mandible being the preferred site of ONJ (52%); both jaws were affected in 5 cases (12%). The most common
precipitating event was dental/periodontal infection (34%), followed by tooth extraction (30%). Oral triggers of ONJ
were missing in 10 cases (23%). This unexpectedly high number of ONJ cases, in comparison with literature data,
suggests that frequency of ONJ in RCC patients might be largely underestimated and suggests a potential role for
targeted agents in the incremental risk of ONJ.
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Up to 35% of advanced renal cell carcinoma (RCC) patients
develop bone metastases during the natural history of their dis-
ease.1-3 Bone involvement in RCC is often associated with the
occurrence of skeletal-related events (SREs), which might greatly
affect the quality of life of diseased patients and have a negative
effect on their survival. In patients with RCC and bone metastases,
the use of drugs that inhibit bone remodeling through different
mechanisms, such as nitrogen-containing bisphosphonates (NBPs)
or denosumab, to prevent SREs is often associated with systemic
targeted therapies. Zoledronic acid has become the most
commonly used NBP in oncology practice, based on the results of
a randomized trial4 and a number of observational studies,2,5
where it has been shown that zoledronic acid not only prolongs
the time to SRE and reduce the number of SRE among patients
with solid tumors and bone metastases, but it might also prolong
survival of RCC patients.
Osteonecrosis of the jaw (ONJ) is a serious adverse event of
treatment with NBPs. ONJ was observed mostly in patients
suffering from multiple myeloma or bone metastatic cancer who
were receiving intravenous NBPs, and, to a lesser extent, in non-
cancer patients treated with oral NBPs.6-9 Recently, the occurrence
of ONJ has also been reported in patients who receive the anti-
receptor activator of nuclear factor kappa-B ligand monoclonal
antibody denosumab and in those treated with antiangiogenic
agents (eg, bevacizumab and sunitinib) alone or combined with
NBPs.10,11
Since the ﬁrst description of ONJ associated with the use of
NBPs for metastatic bone disease in 2003,12 most cases were
observed in metastatic breast and prostate cancer patients. There
was no mention at all of RCC patients in the ﬁrst systematic review
reporting ONJ cases published between 2003 and 200513; and few
ONJ cases in RCC patients have been described afterward.14-17
In recent years the prognosis of advanced RCC patients has
greatly improved, because of the development and registration of
novel targeted agents, directed either against the vascular endothelial
growth factor and its receptors, such as sunitinib, sorafenib, pazo-
panib, axitinib, and bevacizumab, either against the mammalian
target of rapamycin pathway, such as temsirolimus and everolimus.
Since the introduction of these agents into the therapeutic
armamentarium, an increasing number of ONJ cases have been
reported in RCC patients who receive NBPs in association with
targeted agents,18-26 or even in patients who receive targeted agents
alone, mainly sunitinib.27-29 Thus, an interaction between NBPs
and targeted agents toward an increased ONJ risk has been
suggested.20
In November 2010, the European Medicine Agency issued safety
warnings about ONJ risk during sunitinib or bevacizumab treat-
ment.30,31 In consequent “dear doctor” alert letters, manufacturers
reported the following data about ONJ cases registered among pa-
tients treated worldwide in clinical trials or in the postmarketing
setting (in all types of cancer) as follows: 27 ONJ cases among
101,400 patients treated with sunitinib, and 55 ONJ cases among
800,000 patients after bevacizumab treatment31 in all countries in
which the 2 drugs had been used.
We conducted a retrospective study among several Italian
hospital-based care centers that specialize in the diagnosis andClinical Genitourinary Cancer August 2015treatment of ONJ, to assess the occurrence and to investigate the
nature of ONJ in RCC patients given NBPs in combination with
targeted agents.
Materials and Methods
Study Design
We performed a multicenter retrospective study to assess the
occurrence and to investigate the nature of ONJ in RCC patients
receiving NBPs and targeted agents.
Three medical oncology units (Pavia, Alessandria, Pordenone)
and 6 tertiary care centers for oral medicine (Palermo), oral surgery
(Parma, Torino, Bergamo), and maxillofacial surgery (Verona and
Padova) located in different Italian regions actively participated in
the data collection, retrieving data from their ONJ databases.
Hospital notes of consecutive RCC patients diagnosed with ONJ
between December 2007 and August 2013 were reviewed and
relevant clinical data were systematically extracted and entered into a
predeﬁned electronic case report form. The local ethical committee
of each participating center approved the study protocol.
Entry Criteria
Renal cell cancer patients with exposed32 or nonexposed33
bisphosphonate-related ONJ who never underwent head and neck
radiotherapy were eligible for the study. In detail, exposed ONJ was
deﬁned as the presence of longstanding (> 8 weeks) transmucosal
exposure of necrotic jawbone.32 Nonexposed ONJ was comprised
of evidence of otherwise dentally unexplained jawbone pain, ﬁstula,
swelling, mobile teeth, and mandibular fracture, as deﬁned by
Fedele et al and other authors.33-38 In all cases, patients had been
diagnosed by multidisciplinary teams including oral medicine spe-
cialists, maxillofacial surgeons, oncologists, hematologists, and
radiologists.
An additional entry criterion was the exposure to a targeted agent
at the time of ONJ diagnosis.
Study Variables
The following data were collected from the clinical charts of the
patients: (1) age; (2) sex; (3) NBP type; (4) duration of treatment (at
the time of ONJ diagnosis); (5) targeted agent type (ongoing at the
time of ONJ diagnosis or the latest used); (6) duration of treatment;
(7) other targeted agents previously used; (8) ONJ site; and (9)
presence of known risk factors for ONJ (eg, tooth extraction, dental
or periodontal infection, ill-ﬁtting denture, dental implant surgery).
Statistics
Descriptive statistics were calculated on a per-patient basis and
per-site of ONJ. Continuous variables are reported as median and
minimum and maximum values, because of skewed distributions.
Categorical variables were given as the number or percentage of
patients with the characteristic of interest. Statistical analysis was
performed using IBM SPSS Statistics 21.0.
Literature Review
We conducted a PubMed-based and Embase search of the
literature, including articles written in English and other languages,
published between 2003 and 2013, using the query: “bisphospho-
nates, osteonecrosis, jaw or jaws, cancer, RCC, sunitinib, sorafenib,
Table 1 Observed Cases of ONJ in Renal Cell Cancer Patients
Case Sex Age Targeted Agenta Duration, Monthsa Bisphosphonate Duration, Monthsa Site of ONJ Oral Trigger
01 M 59 Sunitinib (sorafenib previously) 6 Ibandronate 4 Mandible None
02 M 71 Sorafenib 6 Zoledronate 36 Mandible Infection
03 M 69 Ridaforolimus 3 Pamidronate 22 NR None
04 M 61 Sunitinib (sorafenib and everolimus
previously)
14 Pamidronate
Zoledronate
2
3
Mandible
Maxilla
None
None
05 M 56 Sunitinib 18 Zoledronate 18 Mandible None
06 M 65 Sunitinib (sorafenib previously) 8 Zoledronate 9 Mandible Tooth extraction
07 M 67 Sunitinib 14 Zoledronate 15 Maxilla Tooth extraction
08 F 68 Sunitinib 20 Zoledronate 1 Maxilla Dental infection
09 M 59 Sunitinib 3 Zoledronate 10 Mandible Tooth extraction
Maxilla Tooth extraction
10 F 62 Sunitinib NR Zoledronate NR Mandible Dental implant
11 M 49 Bevacizumab 4 Zoledronate 4 Mandible Tooth extraction
12 M 72 Sunitinib (sorafenib previously) NR Zoledronate 8 Mandible Infection
13 M 62 Sunitinib (bevacizumab previously) 24 Zoledronate 24 Mandible Oral surgery
14 M 70 Sunitinib NR Zoledronate 28 Maxilla Tooth extraction
15 M 45 Sunitinib NR Zoledronate 1 Mandible Tooth extraction
16 M 59 Sunitinib 13 Zoledronate 16 Maxilla None
17 M 62 Sunitinib 7 Zoledronate 12 Maxilla None
18 M 61 Sunitinib 7 Pamidronate 6 Maxilla Denture
Zoledronate 7
19 M 49 Sunitinib 14 Zoledronate 11 Maxilla Infection
20 M 65 Sunitinib 22 Zoledronate 15 Mandible Infection
21 F 62 Sunitinib 14 Zoledronate 8 Maxilla Infection
22 M 55 Sunitinib 15 Zoledronate 10 Maxilla Infection
23 M 65 Sunitinib 6 Zoledronate 6 Mandible None
24 F 70 Sunitinib 7 Zoledronate 12 Maxilla None
25 M 61 Sorafenib 16 Zoledronate 16 Mandible Tooth extraction
Maxilla Dental implant
26 F 85 Sunitinib 8 Zoledronate 8 Mandible Tooth extraction
27 M 68 Sorafenib 3 Zoledronate 15 Mandible None
28 F 59 Sunitinib (sorafenib previously) 22 Zoledronate 22 Maxilla None
29 M 51 Sunitinib NR Zoledronate 13 Maxilla Tooth extraction
30 M 63 Sunitinib with bevacizumab 26 Zoledronate 22 Mandible Tooth extraction
31 M 57 Sunitinib 1 Zoledronate 7 Maxilla Tooth extraction
32 F 77 Sunitinib 6 Zoledronate 5 Mandible Infection
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290 - Clinical Genitourinary Cancer August 2015everolimus, temsirolimus, targeted therapy.” Only abstracts and
articles citing renal or kidney cancer were selected and examinated.
Further data were derived from renal cancer literature. We also
wrote to authors of some articles to ask for individual patient data, if
not in the published study report.
Results
Data from 44 RCC patients with diagnosed ONJ were included
in this study. The clinical, drug, and dental history of individual
ONJ patients is shown in Table 1.
Osteonecrosis of the jaw patients were mostly male (82%),
with a median age of 63 years (range, 45-85 years). All patients
but 1 were receiving NBPs at the time of ONJ diagnosis. NBPs
were administered according to usual schedules: zoledronic
acid 4 mg intravenously (I.V.) every 3 to 4 weeks, pamidronate
60 to 90 mg I.V. every 4 weeks, and ibandronate 6 mg I.V. every
4 weeks.
Zoledronic acid was the most commonly used NBP (93%): in
39 cases, zoledronic acid was administered from the beginning, and
2 patients given pamidronate had been shifted to zoledronate during
treatment. Of the remaining 3 patients, 2 received only pamidro-
nate, and 1 ibandronate. NBP duration was not available for 1
patient who had received zoledronate. The median duration of
NBPs administration at the time of the ONJ diagnosis was 12
months (range, 1-48 months).
Sunitinib was the most commonly used targeted agent at the
time of ONJ diagnosis (80%); sorafenib was used in 4 cases at the
time of ONJ diagnosis, everolimus in 2, bevacizumab and
interferon in 1; 2 other patients were receiving ridaforolimus
(previously known as deforolimus) and a combination of suniti-
nib and bevacizumab, respectively, as a part of clinical trial.
Duration of treatment with targeted agents was not available
for 5 patients. The median duration of treatment in the
remaining 39 patients was 11 months (range, 1-26 months).
Previous treatments with targeted agents included sorafenib
(6 cases), bevacizumab (1 case), sunitinib (1 case), and everolimus
(1 case).
A total of 49 sites of ONJ were encountered in 44 patients. The
mandible was the preferred site of ONJ (52%), followed by the
maxilla (36%). Both jaws were affected in 5 cases (12%).
Oral triggers of ONJ were not found in 10 cases (23%). The
most common precipitating event was dental/periodontal infection
(34%), followed by tooth extraction (30%), pressure sores caused by
ill-ﬁtting dentures (9%), and other surgical procedures in the oral
cavity (4.5%).
Discussion
Osteonecrosis of the jaw is a well documented adverse event of
treatment with NBPs in metastatic cancer patients, which can nega-
tively affect patient quality of life.39,40 Bisphosphonate-related ONJ
has a multifactorial etiology, with several mechanisms reported,41
including suppression of bone turnover, ischemic bone changes,
infection, and direct toxicity on cells other than osteoclasts. The
antiangiogenic activity of NBPs has been suggested as one of the main
determinants of ONJ onset.42-44 A recent review reported a wide-
ranging ONJ incidence from 0% to 27.5%, relevant to individuals
exposed to intravenous NBP, with a mean incidence of 7%.45
Vittorio Fusco et alThis retrospective exploratory study was aimed at describing the
occurrence and the nature of ONJ associated with the use of NBP
and targeted agents in RCC patients. We found that ONJ is not a
rare occurrence in metastatic RCC patients and that the concomi-
tant use of NBPs and targeted agents, albeit extremely useful for
disease control, is likely to increase the chance of ONJ development.
We also found that the association of zoledronate and sunitinib was
responsible for most of the ONJ cases in RCC patients. One clear
limit of the study is the lack of a denominator to ascertain the ONJTable 2 Cases of ONJ in Renal Cell Cancer Patients Reported in th
First Author (Country) Sex Age Targeted Agent
Ayllon (F)18 Male NR Sunitinib
Brunello (I)19 Male 59 Sunitinib
Christodoulou (GR)20 Male 48 Sunitinib
Wolter (B-F)21 Female 55 Sunitinib
Bozas (UK)22 Male 51 Sunitinib
Hoefert (D)23 Male 55 Sunitinib
Male 56 Sunitinib
Male 62 Sunitinib
Agostino (USA)24 Male 73 Bevacizumab (sunitinib
previously used)
Agrillo (Italy)25 Male 65 Sunitinib
Male 67 Sunitinib with temsirolimus
Balmor (Israel)26 Male 63 Sunitinib
Koch (D)27 Male 59 Sunitinib (sorafenib
previously used)
Fleissig (Israel)28 Female 58 Sunitinib
Nicolatou-Galitis (GR)29 Female 64 Sunitinib
Prati (I)55 Male 60 Temsirolimus
Santos-Silva (Br)56 Male 61 Bevacizumab and
temsirolimus
Giancola (I)57 Male 64 Everolimus
Bozas (UK)58 Male NR Sunitinib
Male 48 Sunitinib
Male 57 Sunitinib
Male 29 Sunitinib
c e e
Beuselinck (F-B)59 5 Patients
(NR)
NR Sunitinib and/or sorafenib
Smidt-Hansen (DK)60 Male 68 Sunitinib
Male 69 Sunitinib
Male 63 Sunitinib
Male 48 Sunitinib
Female 47 Sunitinib
Female 64 Sunitinib
Male 57 Sunitinib
Levin (Israel)61 Female 57 Sunitinibb
Van den Wyngaert (B)62 Male 57b Sunitinibb
Abbreviations: B ¼ Belgium; B-F ¼ Belgium, France; Br ¼ Brasil; D ¼ Germany; DK ¼ Denmark; F
aAt the time of ONJ diagnosis.
bPersonal communication from the authors (unpublished data).
cCase reported in: Bozas et al.58frequency in patients who received combination of NBP and tar-
geted therapy, because of the heterogeneity of involved centers.
Despite the intrinsic limitations of the study due to its retrospective
nature, to our knowledge, this is the largest series of ONJ in RCC
patients treated with bisphosphonates and targeted agents reported
so far.
We performed a comprehensive review of the available English
literature, with the aim of assessing the perceived risk of ONJ in
metastatic RCC patients treated with NBPs and targeted agents.e Literature
Duration,
Monthsa Bisphosphonate
Duration,
Monthsa Oral Trigger
14 Zoledronate 19 NR
4 Zoledronate (previous use) 11 NR
16 Zoledronate 16 NR
16b Zoledronate 16b Tooth extractionb
6 Zoledronate <1 No risk factorsb
9 Ibandronate 9 Tooth extractionb
4 Zoledronate 4 Tooth extractionb
23b Zoledronate 30b Tooth extractionb
12 NR NR NR
12 Zoledronate 12 No risk factors
13 Zoledronate 13 No risk factors
30 Pamidronate 30 Teeth extraction
12 None e Tooth extraction
12 None e Tooth extraction
48 None e Denture
3 None e Tooth extraction
12 None e No risk factors
6 Zoledronate 25 No risk factors
1 Zoledronate 12 Tooth extraction
14 Zoledronate 20 Poor oral hygiene
7 Zoledronate 14 Poor oral hygiene
4 Zoledronate 18 Poor oral hygiene
e e e e
NR NR NR NR
6.5b Zoledronate 3.7b Poor oral Hygiene
16.3b Zoledronate 12.2b Denture
4.2b Zoledronate 4.2b Denture
14.2b Zoledronate 26.2b Dental procedure
3.7b Zoledronate 7.6b Dental procedure
17.7b Zoledronate 6.3b No risk factor
8.2b Zoledronate 11.7b No risk factor
10b Zoledronate 7b No risk factors
9b Zoledronate 27b Tooth extraction
¼ France; F-B ¼ France, Belgium; GR ¼ Greece; I ¼ Italy; ONJ ¼ osteonecrosis of the jaw.
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292 -In the past years, RCC patients were believed to be less prone to
ONJ compared with other solid tumors, by virtue of their limited
survival and the short-term duration of NBP treatment. By the way,
since the introduction of targeted therapies, life expectancy of
metastatic RCC patients has almost tripled in all prognostic risk
groups,46 leading to longer exposure to NBP treatments and an
increased risk of ONJ.
In contrast with the initial ONJ reports, the case series published
more recently included several ONJ cases in RCC patients, with
a frequency ranging from1% to 4.5%of all observedONJ cases.33,47-50
From the integrated analysis of 3 large randomized trials that
compared zoledronic acid and denosumab, the estimated frequency
of ONJ in RCC patients was even greater.51-53 In fact, as already
outlined,54 there were 6 RCC patients among 89 patients treated
with zoledronic acid or denosumab and adjudicated as ONJ cases
(6.7%), whereas the total number of enrolled RCC patients was
155. That means a speciﬁc cancer type ONJ frequency of 3.9% for
RCC patients, which is more than twice the ONJ rate for the entire
patient population (1.6%).
Several reports on the occurrence of ONJ among cancer patients
treated with targeted agents alone or in combination with NBPs
have been also published, and these also included some patients
with RCC, as shown in Table 2.18-29,55-62 As a consequence, tar-
geted agents with antiangiogenic properties are now ascribed as a
possible risk factor for ONJ in cancer patients.
From the only randomized trial that recruited RCC patients,52 it
is neither possible to state whether the 6 RCC patients who
developed ONJ had also received antiangiogenic agents or not, nor
which bone agent was administered.54
Bozas and coworkers58 identiﬁed 5 ONJ cases among 21 RCC
patients treated with a combination of NBP and antiangiogenic
drugs (23.8%), with a cumulative hazard ratio for ONJ of 5% (95%
conﬁdence interval [CI], 0%-10%) and 36% (95% CI, 23%-49%)
after 12 and 24 months of zoledronate treatment, respectively. The
authors’ conclusion suggested a potential synergy of sunitinib and
zoledronic acid in inducing ONJ.
In a similar retrospective study, Beuselinck et al59 found that the
incidence of ONJ among RCC patients increased up to 10% when
NBP and tyrosine kinase inhibitors were used in combination, with
an expected incidence of 17% of ONJ at 24 months.59 The authors
also hypothesized a possible underestimation of ONJ incidence
because of the limited survival of patients in the cohort and the
short duration of NBP treatment of most patients.
Our results are consistent with those of Bozas et al58 and Beu-
selink et al,59 because we also showed a high occurrence of ONJ in
RCC patients.
In the present study an oral trigger was responsible for ONJ
occurrence in most RCC patients treated with NBPs and targeted
agents. A recent report from Smidt-Hansen and coworkers
showed that the rate of ONJ in RCC patients treated with zole-
dronic acid and targeted therapy (sunitinib) decreased from 29%
to 11% when patients underwent oral screening before initiation
of treatment.60
The increasing number of RCC patients being treated with
antiresorptive drugs (NBPs or denosumab) in combination with
antiangiogenic agents underlines the need for careful oral screening
before and during treatment with targeted agents, and the adoptionClinical Genitourinary Cancer August 2015of ONJ preventive protocols already in use for cancer patients
treated with NBPs alone.7,32,63-65
Whether such preventive protocols would also be beneﬁcial for
patients who receive targeted therapy alone (without NBP treat-
ment) should be objects of further research programs.Conclusion
Osteonecrosis of the jaw in metastatic RCC patients given NBPs
and targeted agents in combination is not a rare event. The clinical
features of ONJ resemble those described for bisphosphonate-
related ONJ in other cancer populations.
In the absence of deﬁnite epidemiological data, we would like to
alert the scientiﬁc community that the occurrence of ONJ in RCC
patients receiving NBPs and targeted agents might be reasonably
underestimated, based on the information available from the med-
ical literature and short-term postmarketing drug surveillance
reporting. On the basis of the data reported in our retrospective
exploratory study, prospective research is warranted to better address
the frequency of ONJ in RCC patients who undergo targeted
therapies. Similarly, studies should be performed in patients diag-
nosed with other cancers treated with antiangiogenic therapies.
Hence, clinicians should be aware of this condition and closely
monitor the oral health of RCC patients before and during treat-
ment with antiangiogenic agents used in combination with bone
modiﬁers (NBPs and denosumab).Acknowledgments
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